ADAG

ADAG

Adagene Inc

Net โ€”top 1%Rev โ€”top 1%5Y
Hold

Adagene Inc. is a clinical-stage biotechnology company that researches and develops monoclonal antibody drugs for cancer treatment in China. Its pipeline includes multiple candidates targeting various cancer types using advanced antibody technologies.

โš•๏ธ Healthcare NASDAQ Listed 2021 $ USD
$1,000 invested 5 years ago โ†’$217today

Score Overview

1 Year
Scoreโ€”
Net Growthโ€”
Net Trendโ€”
Net Income Consistencyโ€”
Rev Growthโ€”
Rev Trendโ€”
Revenue Consistencyโ€”
5 Years
Scoreโ€”
Net Growthโ€”
Net Trend50%
Net Income Consistencyโ€”
Rev Growthโ€”
Rev Trend50%
Revenue Consistencyโ€”
All Time
Scoreโ€”
Net Growthโ€”
Net Trend50%
Net Income Consistency
Rev Growthโ€”
Rev Trend50%
Revenue Consistency

See the full market ranking โ†’

Adagene Inc fundamental performance

Across Adagene Inc's full reported history, from 2021 to 2025, revenue declined from $ 10M to $ 7M and net income went from -$ 73M to -$ 17M. Revenue increased in 50% of the years measured; net income in 50%.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-08-12
$ 3.75โ€”
1 Year2025-08-12
$ 1.9196.34%
5 Years2021-08-12
$ 17.30-78.32%
All Time2021-02-09
$ 29.99-87.50%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Year
2026$ 74M
2025$ 7M-$ 17M$ 74M
2024$ 103.2K-$ 33M$ 85M
2023$ 18M-$ 18M$ 109M
2022$ 9M-$ 79M$ 143M
IPO2021$ 10M-$ 73M$ 174M

Explore beyond ADAG

You're looking at Adagene Inc. Members apply the same fundamental framework across all 3,860 companies we cover.

$99/year $149 founding price

Unlock Holder Dashboard

30-day money-back guarantee.

Explore other companies